We have thus investigated directly the TMM activated by tumors in a cohort of 100 gliomas from the Pitié-Salpêtrière Tumor bank, including 92 with ATRX mutations (and 8 histone-mutant without NGS information). This evidence concerns the gene ATRX and central nervous system cancer.